Attractive Growth Opportunities in Parkinson's Disease Treatment Market

Parkinson’s disease treatment is used to treat the symptoms of Parkinson’s disease, generally, medication is the first line treatment for this disease.

 The global Parkinson’s disease treatment market is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1%. Rising geriatric population and government funding for research on Parkinson’s disease are the driving factors for this market.

The Parkinson’s disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region. On the basis of drug class, the Parkinson’s disease treatment market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug.

By distribution channel, the Parkinson’s disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment accounted for the largest share of the market. Increasing number of patient visits to the hospital due to the availability of diagnostic laboratories and presence of skilled neurologists are driving the growth of hospital pharmacies segment.

On the basis of patient care setting, the Parkinson’s disease treatment market is segmented into hospitals and clinics. In 2017, hospitals are expected to account for the largest share of the Parkinson’s disease treatment market. Robust health infrastructure and presence of skilled neurologists are the driving factors for hospital segment.

To Know More @ https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html

Parkinson's Disease Treatment Market Trending in Pharma Industry

“Parkinson’s disease treatment market projected to grow at a CAGR of 6.1%”

The Parkinson’s disease treatment market is expected to grow from USD 4.24 billion in 2017 to USD 5,694.1 million in 2022 to grow at a CAGR of 6.1%. Factors such as the increasing aging population worldwide and government funding for research on Parkinson’s disease are driving this market. However, the availability of alternative treatments is expected to restrain this market.

“The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period”

On the basis of drug class, the Parkinson’s disease treatment market is classified into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by its potency and wide adoption in the treatment of Parkinson’s disease.

“The online pharmacies segment to grow at the fastest rate during the forecast period”

By distribution channel type, the Parkinson’s disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register highest CAGR during the forecast period. Advantages such as 24/7 ordering, home delivery, and discounts on medicines are the driving factors for this segment.

“Europe to hold the largest share of the regional market during the forecast period”

Geographically, the Parkinson’s disease treatment market is dominated by Europe, followed by North America, Asia, and the Rest of the World (RoW). Europe is expected to command the largest share of the Parkinson’s disease treatment market. The large share of this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. The Asian region is estimated to grow at the fastest rate during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

·         By Company Type - Tier 1 – 70% and Tier 2 – 30%

·         By Designation – C-level – 62%, Director Level – 21%, Others – 17%

·         By Region – North America – 50%, Europe – 20%, Asia – 30%

To Know More @https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html

Parkinson's Disease Treatment Market 2018- Industry Growth, Size , Share, Analysis and Global Forecast to 2022

"Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022"

The Parkinsons disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%.

The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinsons disease and government funding for research.

Browse 66 Market Data Tables

33 Figures 

113 Pages and in-depth TOC on "Parkinson's Disease Treatment Market
https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html
Early buyers will receive 10% customization on reports.

By drug class, the carbidopa/levodopa segment is estimated to dominate the market in 2017

On the basis of drug class, the Parkinson’s disease therapeutic drugs market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO inhibitors, COMT inhibitors, anticholinergics, and other drugs. In 2017, the carbidopa/levodopa segment is expected to account for the largest share of the market. Carbidopa/levodopa drugs are more potent than most other drug classes are hence widely used in the treatment of Parkinson’s disease.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247

By distribution channel, the hospital pharmacies segment is estimated to hold the largest share of the market in 2017

By distribution channel, the Parkinson’s disease therapeutic drugs market has been segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment is expected to account for the largest share of the market. The large share of this segment can primarily be attributed to the availability of a wide range of drugs in these facilities and the increasing number of patient visits to hospitals.

Hospitals to dominate the Parkinsons disease treatment market during the forecast period

The Parkinsons disease treatment market is classified by patient care settings into hospitals and clinics. In 2017, the hospital segment is expected to command the largest share and is estimated to grow at the fastest rate as compared to clinics segment. This market is mainly driven by robust healthcare services provided in hospitals and the presence of skilled neurologists in the hospitals.

Asia to offer lucrative growth opportunities

By region, the global Parkinsons disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While Europe is expected to hold the largest share of the market in 2017, Asia is expected to grow at the highest CAGR during the forecast period. Increasing number of players in the region and the rising aging population are some major factors driving the high growth of this regional segment.

Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany),  Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

Speak To Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=47265247

Target Audience:

• Parkinson’s disease treatment product manufacturers
• Parkinson’s disease treatment dealers and suppliers
• Human identification service providers
• Parkinson’s disease associations
• Academic institutions
• Venture capitalists
• Consulting firms
• Government bodies

Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson’s Disease

Parkinson’s disease therapeutic drugs act upon the central nervous system to control or reduce the symptoms of Parkinson’s disease. 

The global Parkinson’sdisease treatment market is expected to reach USD 5.69 billion by 2022 from USD4.24 billion in 2017, at a CAGR of 6.1%.

Globally, the Parkinson’s disease treatment market is witnessing a moderate growth due to factors such as increasing prevalence of Parkinson’s disease; rising geriatric population; and support for research on Parkinson’s disease. 

Over the last few decades, key players operating in this market are focusing on offering new and innovative products. Based on drug class, the Parkinson’s disease therapeutic drugs market is segmented into carbidopa/levodopa dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period. This is due to carbidopa/levodopa drugs are more potent and widely used in the treatment of Parkinson’s disease in comparison to other therapeutic drugs.

Downloadn FREE Brochure @  https://www.marketsandmarkets.com/pdfdownload.asp?id=47265247

By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register the highest growth rate during the forecast period. Advancements such as 24/7 availability, home delivery, and discount on medicines are driving factors for online pharmacies segment.

On the basis of patient care setting, the market is categorized into hospitals and clinics. The hospitals segment is estimated to grow at the fastest rate during the forecast period. The growth of this segment can be attributed to the availability of diagnostics laboratories in the hospital and the presence skilled neurologists.

The Parkinson’s disease treatment market is classified based on regions into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Presence key market players and rising aging population are the major factors driving the Parkinson’s disease treatment market in this region.

Future of Parkinson's Disease Treatment Market

Parkinson’s disease therapeutic drugs act upon the central nervous system to control or reduce the symptoms of Parkinson’s disease. The global Parkinson’s disease treatment market is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1%.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=47265247

Globally, the Parkinson’s disease treatment market is witnessing a moderate growth due to factors such as increasing prevalence of Parkinson’s disease; rising geriatric population; and support for research on Parkinson’s disease. 

Over the last few decades, key players operating in this market are focusing on offering new and innovative products. Based on drug class, the Parkinson’s disease therapeutic drugs market is segmented into carbidopa/levodopa dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period. This is due to carbidopa/levodopa drugs are more potent and widely used in the treatment of Parkinson’s disease in comparison to other therapeutic drugs.

By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register the highest growth rate during the forecast period. Advancements such as 24/7 availability, home delivery, and discount on medicines are driving factors for online pharmacies segment.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=47265247

On the basis of patient care setting, the market is categorized into hospitals and clinics. The hospitals segment is estimated to grow at the fastest rate during the forecast period. The growth of this segment can be attributed to the availability of diagnostics laboratories in the hospital and the presence skilled neurologists.

The Parkinson’s disease treatment market is classified based on regions into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Presence key market players and rising aging population are the major factors driving the Parkinson’s disease treatment market in this region. 

Parkinson's Disease Treatment Market Worth 5.69 Billion USD by 2022

Parkinson’s disease therapeutic drugs act upon the central nervous system to control or reduce the symptoms of Parkinson’s disease. The global Parkinson’s disease treatment market is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1%.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=47265247

Globally, the Parkinson’s disease treatment market is witnessing a moderate growth due to factors such as increasing prevalence of Parkinson’s disease; rising geriatric population; and support for research on Parkinson’s disease. 

Over the last few decades, key players operating in this market are focusing on offering new and innovative products. Based on drug class, the Parkinson’s disease therapeutic drugs market is segmented into carbidopa/levodopa dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period. This is due to carbidopa/levodopa drugs are more potent and widely used in the treatment of Parkinson’s disease in comparison to other therapeutic drugs.

By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register the highest growth rate during the forecast period. Advancements such as 24/7 availability, home delivery, and discount on medicines are driving factors for online pharmacies segment.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=47265247

On the basis of patient care setting, the market is categorized into hospitals and clinics. The hospitals segment is estimated to grow at the fastest rate during the forecast period. The growth of this segment can be attributed to the availability of diagnostics laboratories in the hospital and the presence skilled neurologists.

The Parkinson’s disease treatment market is classified based on regions into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Presence key market players and rising aging population are the major factors driving the Parkinson’s disease treatment market in this region.